Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Helix BioPharma Corp.TSX: HBP.TO
Depreciation & Amortization · Q3 FY2026 · quarter ended Apr 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of CA$1K fell 66.7% year over year, behind the -58.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -66.7% toward the trailing-twelve-month pace of -58.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
CAD · from the cash flow
- Latest · FY2025
- 10K CAD
- Year-over-year change
- -28.6%
- 4-year CAGR
- -52.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 10K | -28.6% |
| FY2024 | 2024-07-31 | 14K | +7.7% |
| FY2023 | 2023-07-31 | 13K | +8.3% |
| FY2022 | 2022-07-31 | 12K | -94.0% |
| FY2021 | 2021-07-31 | 199K | — |
Depreciation & Amortization vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -58.3% is the 3rd highest of 4, against a peer median of -40.2%.
- Over three fiscal years its annual growth of -5.9% compares with a peer median of -18.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.99M USD | -0.8% | -13.6% | 39.4% | |
| LTM Apr 2026 | CA$256.13K CAD | -40.2% | -8.0% | — | |
| LTM Mar 2026 | CA$103.71K CAD | -69.2% | -22.6% | — | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $6.4K USD | — | -77.2% | — |
| LTM Apr 2026 | CA$5K CAD | -58.3% | -5.9% | — | |
| Peer median (excluding HBP.TO) | — | -40.2% | -18.1% | 39.4% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Net Income | (8.04M) | (6.56M) | (6.29M) | (9.26M) | (5.21M) |
| Depreciation & Amortization | 199K | 12K | 13K | 14K | 10K |
| Deferred Income Tax | (2.22M) | 9K | 0 | 0 | 0 |
| Stock-Based Compensation | 664K | 425K | 570K | 3.52M | 0 |
| Change in Working Capital | (54K) | (892K) | 186K | 485K | 1.33M |
| Accounts Receivables | (173K) | 74K | 217K | 8K | (68K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 50K | (867K) | (106K) | 0 | 0 |
| Other Working Capital | 69K | (99K) | 75K | 477K | 1.4M |
| Other Non-Cash Items | 142K | 500K | (5K) | 31K | 31K |
| Operating Cash Flow | (9.3M) | (6.51M) | (5.53M) | (5.22M) | (3.83M) |
| Capital Expenditures | 0 | 0 | (10K) | (14K) | (2K) |
| Acquisitions (Net) | 2.02M | 0 | 5K | 0 | 19K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.02K | 0 | 5K | 0 | 0 |
| Investing Cash Flow | 2.02M | 0 | (5K) | (14K) | 17K |
| Debt Repayment | 3M | 0 | (2.06M) | 0 | 0 |
| Common Stock Issued | 3.56M | 2.99M | 4.15M | 5.51M | 2.8M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.56M | 3.21M | 999K | 0 | 0 |
| Financing Cash Flow | 6.56M | 6.21M | 3.09M | 5.51M | 2.8M |
| Effect of Forex Changes | 52K | (9K) | 0 | 0 | 0 |
| Net Change in Cash | (670K) | (313K) | (2.44M) | 273K | (1.02M) |
| Free Cash Flow | (9.3M) | (6.51M) | (5.54M) | (5.23M) | (3.83M) |
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.